Dr. Savage’s Ph. D. in epidemiology and nutrition sciences make him uniquely qualified to comment on some of the failings of the American medical system, but most interestingly, his chapter on health care focuses on what was wrong with the system before Obamacare. The FDA is a primary target for Savage, who makes the case that Trump must overhaul the agency to lower costs and promote competition amongst pharmaceutical companies. He illustrates this argument with the example of Mylan’s EpiPen, the price of which rose 540 percent over nine years. To quote Savage, "If Mylan had even two or three other competitors, do you think they would have been able to raise the price of the EpiPen more than 540 percent in nine years? 